When selecting a new contract manufacturer for a biomanufacturing project, Manufacturing/Production personnel hold the greatest average influence at 18%, according to ISR’s Bioprocessing Market Outlook 2025–2030. Executive Management and R&D follow closely, each accounting for 15% of decision-making influence. Department
A once-niche manufacturing technology is going mainstream, as biopharma’s biggest players bet billions on replacing batch production with “always-on” continuous bioprocessing. According to Astute Analytica’s 2026 market report, the continuous bioprocessing market was valued at $319.77 million in 2025 and
“If you can’t demonstrate international quality standards, nobody is going to take a chance on a million-dollar batch to save a few dollars on their manufacturing. It just won’t happen.” Eric Langer is President of BioPlan Associates, where he has
